【摘要】 目的 研究HBV DNA前C区1896位变异,BCP区1762/1764位变异与干扰素α治疗应答的关系。方法 以41例接受干扰素治疗的HBeAg阳性慢性乙型肝炎(慢乙肝)患者为研究对象。治疗前取患者外周血清,采用PCR技术扩增前C区、BCP区,并测序分析。同时监测治疗0、12、24周患者外周血ALT、HBsAg、HBeAg、HBV DNA水平。结果(1)PC/BCP区变异(突变型,non-WT)患者HBeAg转阴率(n=13,72.29%)高于未发生PC/BCP变异(野生型,WT)患者(n=4,28.8%)(P=0.014);(2)突变组HBsAg降低(n=5,56.7%)、HBVDNA转阴(n=8,53.5%),完全应答(n=5,62.5%),野生组HBsAg降低(n=6,43.3%)、HBV DNA转阴(n=7,46.7%),完全应答(n=3,37.5%),2组间无明显差异。结论 突变型患者HBeAg转阴率高于野生型患者。更多还原

【Abstract】 Objective To investigate the relationship between the precore 1896 and/or the basal core promoter(BCP) 1762/1764 mutations and patient response for IFN-α treatment.Methods Forty-one patients with HBeAg-positive chronic hepatitis B who received IFN-α therapy were enrolled in this study.Serum HBVDNA was extracted from peripheral blood before treatment,then polymerase chain reaction(PCR) was performed to sequence PC/BCP gene fragments.Meanwhile,we monitored the amounts of ALT,HBsAg,HBeAg and HBV DNA at weeks 0,12 and 24.Results(1) More patients with PC/BCP mutants(non-wild-type,non-WT) present HBeAg negative status(n=13,72.2%) than those without PC/BCP mutation(wild-type,WT)(n=4,28.8%)(P=0.04).(2)For non-WT patients,their levels of HBsAg are decreased(n=5,56.7%).while they manifest HBVDNA negative status(n=8,53.5%),and complete response(n= 5,62.5%).For WT patients,their levels of HBsAg are decreased(n=6,43.3%),while they also manifest HBV DNA negative status(n=7,46.7%),and complete response(n=3,37.5%).There is no significant difference between the two groups.Conclusion More non-WT patients present HBeAg negative status than WT patients.更多还原